The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 26, 2017
Filed:
Mar. 13, 2014
Applicant:
Flatley Discovery Lab, Llc, Charlestown, MA (US);
Inventors:
Michael P. Zawistoski, West Warwick, RI (US);
Yevgen Barsukov, Brookline, MA (US);
Bridget M. Cole, Quincy, MA (US);
Richard A. Nugent, Ashland, MA (US);
Assignee:
FLATLEY DISCOVERY LAB, LLC, Charlestown, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07D 405/14 (2006.01); A61K 31/4468 (2006.01); C07D 211/96 (2006.01); A61K 31/437 (2006.01); C07D 471/04 (2006.01); C07D 401/12 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); C07D 401/14 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); A61K 31/4245 (2006.01); A61K 31/443 (2006.01); A61K 31/4525 (2006.01); A61K 31/4725 (2006.01); A61K 31/7036 (2006.01);
U.S. Cl.
CPC ...
C07D 211/96 (2013.01); A61K 31/4245 (2013.01); A61K 31/437 (2013.01); A61K 31/443 (2013.01); A61K 31/4468 (2013.01); A61K 31/454 (2013.01); A61K 31/4525 (2013.01); A61K 31/4545 (2013.01); A61K 31/4725 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61K 31/7036 (2013.01); A61K 45/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01);
Abstract
The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof: